Amarin Corporation plc
NASDAQ:AMRN · NASDAQ Global Market
+$0.29 today
Vol 0.09M · Avg 0.07M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$38.8M +52.8% | -$82.2M -38.5% | -$59.3M +43.9% | -$105.7M -1468.2% | $7.7M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $3.0M +0.5% | $3.0M +1.2% | $3.0M -3.8% | $3.1M +8.3% | $2.9M | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $13.9M -21.3% | $17.7M | $0 | $0 | $0 | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | $32.3M -10.8% | $36.2M -29.5% | $51.3M +149.3% | -$104.0M +10.3% | -$116.0M | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | -$3.8M -134.2% | $11.2M +580.7% | -$2.3M -107.1% | $33.0M +495.5% | -$8.3M | $592.6M | $1.3B | $626.2M |
| Inventory | $35.0M -66.8% | $105.4M +87.2% | $56.3M +254.8% | -$36.4M +78.2% | -$167.0M | $1.0B | $1.2B | $1.1B |
| Accounts Payables | $14.5M +118.9% | -$77.0M -46681.7% | -$164.6K +99.8% | -$102.7M -299.3% | $51.5M | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | -$13.4M -282.8% | -$3.5M -36.3% | -$2.6M -223.6% | $2.1M -73.7% | $7.9M | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | -$3.7M +35.3% | -$5.7M -147.8% | $12.0M -55.0% | $26.7M -31.4% | $38.9M | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | $6.7M +121.7% | -$31.0M -549.3% | $6.9M +103.8% | -$180.0M -170.5% | -$66.5M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | $0 -100.0% | $2 +100.0% | -$24.1K -1277352.7% | -$2 -178.2% | $2 | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | $0 | $0 | $0 | $0 -100.0% | $4.0K | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | -$200.9M +27.9% | -$278.8M -29.1% | -$215.9M -164.7% | -$81.6M +71.9% | -$290.2M | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $209.8M -9.9% | $232.8M +22.0% | $190.8M -25.8% | $257.4M -34.7% | $394.2M | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | $0 | $0 | $0 | $0 | $0 | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | $8.8M +119.2% | -$46.0M -79.4% | -$25.6M -114.6% | $175.2M +68.3% | $104.1M | $4.8B | $6.4B | $5.1B |
| Debt Repayment | $0 | $0 | $0 | $0 | $0 | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $140.3K +7.1% | $131.1K -94.1% | $2.2M +234.1% | $664.6K -85.5% | $4.6M | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | -$2.2M -38.4% | -$1.6M +20.9% | -$2.0M -90.7% | -$1.0M +89.2% | -$9.6M | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | -$2.0M -41.3% | -$1.4M -725.0% | $230.9K +161.0% | -$378.8K +92.5% | -$5.1M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | -$31.6K -195.7% | $33.0K -53.8% | $71.4K +2331.6% | -$3.2K -182.6% | $3.9K | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | $13.5M +117.2% | -$78.4M -326.0% | -$18.4M -255.2% | -$5.2M -116.0% | $32.5M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | $6.7M +121.7% | -$31.0M -550.7% | $6.9M +103.8% | -$180.0M -170.5% | -$66.5M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Alto Neuroscience, Inc.
NYSE:ANRO
$782.59M
DBV Technologies S.A.
NASDAQ:DBVT
$378.32M
Silence Therapeutics plc
NASDAQ:SLN
$326.39M
Cellectis S.A.
NASDAQ:CLLS
$307.28M
Larimar Therapeutics, Inc.
NASDAQ:LRMR
$305.94M
Lyell Immunopharma, Inc.
NASDAQ:LYEL
$293.31M
AC Immune S.A.
NASDAQ:ACIU
$241.41M
Altimmune, Inc.
NASDAQ:ALT
$238.81M
Korro Bio, Inc.
NASDAQ:KRRO
$128.50M
enGene Holdings Inc.
NASDAQ:ENGN
$88.57M
SEC Filings
Recent regulatory filings
No filings found.
Does AMRN generate free cash flow?
Amarin Corporation plc (AMRN) generated $6.74M of free cash flow in fiscal 2025.
How much operating cash flow does AMRN produce?
Operating cash flow was $6.74M, before capital expenditures of $0.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.